Literature DB >> 24530025

Resolution of inflammation is altered in Alzheimer's disease.

Xiuzhe Wang1, Mingqin Zhu1, Erik Hjorth1, Veronica Cortés-Toro1, Helga Eyjolfsdottir2, Caroline Graff2, Inger Nennesmo3, Jan Palmblad4, Maria Eriksdotter2, Kumar Sambamurti5, Jonathan M Fitzgerald6, Charles N Serhan6, Ann-Charlotte Granholm5, Marianne Schultzberg7.   

Abstract

BACKGROUND: Resolution is the final stage of the inflammatory response, when restoration of tissue occurs. Failure may lead to chronic inflammation, which is known as part of the pathology in the brain of individuals with Alzheimer's disease (AD).
METHODS: Specialized pro-resolving mediators (SPMs), receptors, biosynthetic enzyme, and downstream effectors involved in resolution were analyzed in postmortem hippocampal tissue from AD patients and non-AD subjects. SPMs were analyzed in cerebrospinal fluid (CSF).
RESULTS: SPMs and SPM receptors were detected in the human brain. Levels of the SPM lipoxin A4 (LXA4) were reduced in AD, both in the CSF and hippocampus. An enzyme involved in LXA4 synthesis and two SPM receptors were elevated in AD brains. LXA4 and RvD1 levels in CSF correlated with Mini-Mental State Examination (MMSE) scores.
CONCLUSIONS: A resolution pathway exists in the brain and the alterations described herein strongly suggest a dysfunction of this pathway in AD. MMSE correlations suggest a connection with cognitive function in AD.
Copyright © 2015 The Alzheimer's Association. All rights reserved.

Entities:  

Keywords:  15-Lipoxygenase-2; ALX/FPR2; ChemR23; ELISA; FPRL1; Human; Immunohistochemistry; Lipoxin A(4); Mild cognitive impairment; Resolvin D1; Specialized pro-resolving mediators; Tau

Mesh:

Substances:

Year:  2014        PMID: 24530025      PMCID: PMC4275415          DOI: 10.1016/j.jalz.2013.12.024

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  48 in total

1.  A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease.

Authors:  Walter J Lukiw; Jian-Guo Cui; Victor L Marcheselli; Merete Bodker; Anja Botkjaer; Katherine Gotlinger; Charles N Serhan; Nicolas G Bazan
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

2.  Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease.

Authors:  Milos D Ikonomovic; Eric E Abrahamson; Tolga Uz; Hari Manev; Steven T Dekosky
Journal:  J Histochem Cytochem       Date:  2008-08-04       Impact factor: 2.479

3.  Resolvin D1 binds human phagocytes with evidence for proresolving receptors.

Authors:  Sriram Krishnamoorthy; Antonio Recchiuti; Nan Chiang; Stephanie Yacoubian; Chih-Hao Lee; Rong Yang; Nicos A Petasis; Charles N Serhan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

Review 4.  NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies.

Authors:  Patrick L McGeer; Edith G McGeer
Journal:  Neurobiol Aging       Date:  2006-05-11       Impact factor: 4.673

5.  Lipoxin A4 inhibits IL-1beta-induced IL-8 and ICAM-1 expression in 1321N1 human astrocytoma cells.

Authors:  Yann Decker; Gethin McBean; Catherine Godson
Journal:  Am J Physiol Cell Physiol       Date:  2009-04-08       Impact factor: 4.249

6.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

Authors:  Oskar Hansson; Henrik Zetterberg; Peder Buchhave; Elisabet Londos; Kaj Blennow; Lennart Minthon
Journal:  Lancet Neurol       Date:  2006-03       Impact factor: 44.182

7.  Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke.

Authors:  Mónica Sobrado; Marta P Pereira; Iván Ballesteros; Olivia Hurtado; David Fernández-López; Jesús M Pradillo; Javier R Caso; José Vivancos; Florentino Nombela; Joaquín Serena; Ignacio Lizasoain; María A Moro
Journal:  J Neurosci       Date:  2009-03-25       Impact factor: 6.167

8.  Association of IL10 promoter polymorphism in Italian Alzheimer's disease.

Authors:  Silvia Bagnoli; Elena Cellini; Andrea Tedde; Benedetta Nacmias; Silvia Piacentini; Valentina Bessi; Laura Bracco; Sandro Sorbi
Journal:  Neurosci Lett       Date:  2007-03-19       Impact factor: 3.046

9.  The required role of endogenously produced lipoxin A4 and annexin-1 for the production of IL-10 and inflammatory hyporesponsiveness in mice.

Authors:  Danielle G Souza; Caio T Fagundes; Flavio A Amaral; Daniel Cisalpino; Lirlândia P Sousa; Angélica T Vieira; Vanessa Pinho; Jacques R Nicoli; Leda Q Vieira; Iolanda M Fierro; Mauro M Teixeira
Journal:  J Immunol       Date:  2007-12-15       Impact factor: 5.422

Review 10.  Resolution of inflammation: state of the art, definitions and terms.

Authors:  Charles N Serhan; Sue D Brain; Christopher D Buckley; Derek W Gilroy; Christopher Haslett; Luke A J O'Neill; Mauro Perretti; Adriano G Rossi; John L Wallace
Journal:  FASEB J       Date:  2007-02       Impact factor: 5.191

View more
  94 in total

Review 1.  Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms.

Authors:  Charles N Serhan
Journal:  FASEB J       Date:  2017-01-13       Impact factor: 5.191

Review 2.  Essential Dietary Bioactive Lipids in Neuroinflammatory Diseases.

Authors:  Maria Valeria Catani; Valeria Gasperi; Tiziana Bisogno; Mauro Maccarrone
Journal:  Antioxid Redox Signal       Date:  2017-07-24       Impact factor: 8.401

Review 3.  Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology.

Authors:  Charles N Serhan
Journal:  Mol Aspects Med       Date:  2017-03-03

Review 4.  Omega-3 Polyunsaturated Fatty Acids and Oxylipins in Neuroinflammation and Management of Alzheimer Disease.

Authors:  Jessay Gopuran Devassy; Shan Leng; Melissa Gabbs; Md Monirujjaman; Harold M Aukema
Journal:  Adv Nutr       Date:  2016-09-15       Impact factor: 8.701

Review 5.  Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors.

Authors:  Nan Chiang; Charles N Serhan
Journal:  Mol Aspects Med       Date:  2017-03-31

Review 6.  Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.

Authors:  Charles N Serhan; Bruce D Levy
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

Review 7.  Modulation of innate immunity of patients with Alzheimer's disease by omega-3 fatty acids.

Authors:  Milan Fiala; Gijs Kooij; Karen Wagner; Bruce Hammock; Matteo Pellegrini
Journal:  FASEB J       Date:  2017-04-18       Impact factor: 5.191

Review 8.  Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis.

Authors:  Insha Zahoor; Shailendra Giri
Journal:  Clin Rev Allergy Immunol       Date:  2021-04       Impact factor: 8.667

9.  A single meal has the potential to alter brain oxylipin content.

Authors:  J E Norman; H H Aung; Y Otoki; Z Zhang; A Y Taha; J C Rutledge
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2020-01-30       Impact factor: 4.006

10.  Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42 Phagocytosis.

Authors:  Mingqin Zhu; Xiuzhe Wang; Erik Hjorth; Romain A Colas; Lisa Schroeder; Ann-Charlotte Granholm; Charles N Serhan; Marianne Schultzberg
Journal:  Mol Neurobiol       Date:  2015-12-09       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.